Key facts
- It has raised $51.1M; the latest was Early Stage VC ($1.1M) in Jul 2024.
- Notable investors include Flagship Pioneering, Coalition for Epidemic Preparedness Innovations, Global Health Investment Corporation.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Apriori Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Apriori Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Apriori Bio
Operator of a health security company intended to protect against viral threats. The company's approach centers on a technology platform, which allows a survey of the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the threatening variants.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 23
- Website
- aprioribio.com/
- Ownership
- Privately Held (backing)
Apriori Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apriori Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apriori Bio in its N-PORT filings yet. We sweep new filings monthly.